Vontobel Holding
TRVI icon

Vontobel Holding’s Trevi Therapeutics TRVI Stock Holding History

Vontobel Holding’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$187K Sell
10,053
-362
-3% -$5.26K ﹤0.01% 1365
2026
Q1 		$124K Sell
10,415
-349
-3% -$3.91K ﹤0.01% 1136
2025
Q4 		$135K Sell
10,764
-11,095
-51% -$128K ﹤0.01% 1340
2025
Q3 		$200K Sell
21,859
-3,041
-12% -$22.8K ﹤0.01% 1233
2025
Q2 		$136K Sell
24,900
-6,459
-21% -$40.2K ﹤0.01% 1200
2025
Q1 		$197K Buy
+31,359
New +$150K ﹤0.01% 1015

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Vontobel Holding's TRVI Position: Q2 2026 in Review

Vontobel Holding reduced its Trevi Therapeutics (TRVI) stake by 3.5% in Q2 2026, selling an estimated $5.26K and leaving 10,053 shares worth $187K. The position accounts for ﹤0.01% of the portfolio, ranked #1365.

Vontobel Holding first reported a position in TRVI in Q1 2025 and has held it in 6 quarters since. The position peaked at $200K in Q3 2025. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Vontobel Holding held 10,053 shares of Trevi Therapeutics worth $187K as of Q2 2026.
  • Vontobel Holding sold 362 Trevi Therapeutics shares in Q2 2026, an estimated $5.26K.
  • Trevi Therapeutics made up ﹤0.01% of Vontobel Holding's portfolio in Q2 2026, its #1365 holding.
  • Vontobel Holding first reported a position in Trevi Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Vontobel Holding's Trevi Therapeutics position peaked at $200K in Q3 2025.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Vontobel Holding's 13F filing for Q2 2026, filed 3 Aug 2026.